Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Stem Cell Culture01:17

Stem Cell Culture

5.3K
Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...
5.3K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

72.0K
Overview
72.0K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.0K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.0K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Beta cell reactivity defines disease-relevant pancreatic CD8 T cells in type 1 diabetes.

bioRxiv : the preprint server for biology·2026
Same author

Hemoglobin-albumin-lymphocyte-platelet score associated with diabetic foot severity, unlike modified systemic immune-inflammatory index and modified systemic inflammatory response index.

Frontiers in endocrinology·2026
Same author

Solar radiation prediction using multivariate signal decomposition and physics-informed time-frequency feature extraction.

Communications engineering·2026
Same author

In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial.

Blood advances·2026
Same author

Facile induction of immune tolerance by an interleukin-2-TGFβ surrogate agonist.

Nature·2026
Same author

Dual CD8 and TCR editing in regulatory T cells mediates HLA-A2-restricted tissue-specific homing.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

関連する実験動画

Updated: Sep 8, 2025

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

8.8K

反対: 幹細胞 治療 と 免疫 システム

Roberto Castro-Gutierrez1, Qizhi Tang2

  • 1Diabetes Center, University of California San Francisco, San Francisco, USA; Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, USA.

Cell stem cell
|September 5, 2025
PubMed
まとめ

幹細胞治療は,HLAの不一致により,免疫拒絶の課題に直面します. 臨床試験の分析により 細胞治療の成果を上げるための リスク軽減戦略が明らかになりました

さらに関連する動画

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE
09:24

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

17.8K
In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

533

関連する実験動画

Last Updated: Sep 8, 2025

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

8.8K
Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE
09:24

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

17.8K
In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

533

科学分野:

  • 免疫学
  • 再生医療
  • 臨床試験

背景:

  • 幹細胞治療は急速に進歩し 様々な臨床応用が期待されています
  • 幹細胞治療の重要な障害は 宿主による免疫拒絶の危険性です
  • 人間の白血球抗原 (HLA) の不一致は,この免疫反応の主な要因です.

研究 の 目的:

  • 現在進行中の幹細胞治療の臨床試験における免疫拒絶の課題を調査する.
  • 細胞治療の有効性に対するHLAミスマッチと免疫抑制の影響を分析する.
  • 幹細胞治療における免疫リスクの軽減のための潜在的な戦略を特定する.

主な方法:

  • 進行中の細胞療法試験からの最近の臨床報告と免疫学的分析のレビュー.
  • HLAの適合性に関する患者の免疫反応の評価
  • 免疫抑制プロトコルとその効果の評価

主要な成果:

  • 臨床データは,幹細胞受容者におけるHLA不一致に関連した重大な課題を強調しています.
  • 免疫抑制の戦略は,拒絶を予防する点で変化する成功を示しています.
  • 特定の免疫学的マーカーは治療結果と相関する.

結論:

  • HLAの不一致を理解することは 幹細胞移植の成功に不可欠です
  • 免疫抑制とドナーマッチングの最適化により 細胞治療の安全性と有効性が向上します
  • 幹細胞治療を進めるために 免疫耐性メカニズムに関するさらなる研究が必要である.